{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:35:42Z","timestamp":1790472942276,"version":"4.1.0"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013132","name":"Combat Casualty Care Research Program","doi-asserted-by":"publisher","award":["H_001_2018_WRAIR (FY18-23)"],"award-info":[{"award-number":["H_001_2018_WRAIR (FY18-23)"]}],"id":[{"id":"10.13039\/100013132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013132","name":"Combat Casualty Care Research Program","doi-asserted-by":"publisher","award":["CO240012_WRAIR (FY24-26)"],"award-info":[{"award-number":["CO240012_WRAIR (FY24-26)"]}],"id":[{"id":"10.13039\/100013132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeting drugs to the mitochondrial level shows great promise for acute and chronic treatment of traumatic brain injury (TBI) in both military and civilian sectors. Perhaps the greatest obstacle to the successful delivery of drug therapies is the blood brain barrier (BBB). Intracerebroventricular and intraparenchymal routes may provide effective delivery of small and large molecule therapies for preclinical neuroprotection studies. However, clinically these delivery methods are invasive, and risk inadequate exposure to injured brain regions due to the rapid turnover of cerebral spinal fluid. The direct intranasal drug delivery approach to therapeutics holds great promise for the treatment of central nervous system (CNS) disorders, as this route is non-invasive, bypasses the BBB, enhances the bioavailability, facilitates drug dose reduction, and reduces adverse systemic effects. Using the intranasal method in animal models, researchers have successfully reduced stroke damage, reversed Alzheimer\u2019s neurodegeneration, reduced anxiety, improved memory, and delivered neurotrophic factors and neural stem cells to the brain. Based on literature spanning the past several decades, this review aims to highlight the advantages of intranasal administration over conventional routes for TBI, and other CNS disorders. More specifically, we have identified and compiled a list of most relevant mitochondria-targeted neuroprotective compounds for intranasal administration based on their mechanisms of action and pharmacological properties. Further, this review also discusses key considerations when selecting and testing future mitochondria-targeted drugs given intranasally for TBI.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s12967-024-04908-2","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T12:02:08Z","timestamp":1708084928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Intranasal delivery of mitochondria targeted neuroprotective compounds for traumatic brain injury: screening based on pharmacological and physiological properties"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-5792","authenticated-orcid":false,"given":"Jignesh D.","family":"Pandya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Musyaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiren R.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Starlyn L.","family":"Okada-Rising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke H.","family":"Scultetus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"issue":"6","key":"4908_CR1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3171\/jns.2001.95.6.0979","volume":"95","author":"CG Markgraf","year":"2001","unstructured":"Markgraf CG, Clifton GL, Moody MR. Treatment window for hypothermia in brain injury. J Neurosurg. 2001;95(6):979\u201383.","journal-title":"J Neurosurg"},{"key":"4908_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.mcn.2017.06.004","volume":"83","author":"R Baratz-Goldstein","year":"2017","unstructured":"Baratz-Goldstein R, Toussia-Cohen S, Elpaz A, Rubovitch V, Pick CG. Immediate and delayed hyperbaric oxygen therapy as a neuroprotective treatment for traumatic brain injury in mice. Mol Cell Neurosci. 2017;83:74\u201382.","journal-title":"Mol Cell Neurosci"},{"issue":"6","key":"4908_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/00001199-199912000-00009","volume":"14","author":"DJ Thurman","year":"1999","unstructured":"Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain injury in the United States: a public health perspective. J Head Trauma Rehabil. 1999;14(6):602\u201315.","journal-title":"J Head Trauma Rehabil"},{"key":"4908_CR4","unstructured":"Georges A. Traumatic brain injury. 2017."},{"issue":"9233","key":"4908_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(00)02689-1","volume":"356","author":"J Ghajar","year":"2000","unstructured":"Ghajar J. Traumatic brain injury. The Lancet. 2000;356(9233):923\u20139.","journal-title":"The Lancet"},{"issue":"11","key":"4908_CR6","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3109\/02699052.2015.1065344","volume":"29","author":"DG Stein","year":"2015","unstructured":"Stein DG. Embracing failure: what the phase III progesterone studies can teach about TBI clinical trials. Brain Inj. 2015;29(11):1259\u201372.","journal-title":"Brain Inj"},{"key":"4908_CR7","unstructured":"Dickey N, Jenkins D, Butler FK. Prehospital Use of Ketamine in Battlefield Analgesia 2012\u201303. Falls Church, Virginia USA: Defense Health Board, Memorandum. 2012."},{"issue":"10","key":"4908_CR8","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/j.1582-4934.2010.01164.x","volume":"14","author":"TM Andriessen","year":"2010","unstructured":"Andriessen TM, Jacobs B, Vos PE. Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J Cell Mol Med. 2010;14(10):2381\u201392.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"4908_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.nurt.2009.10.019","volume":"7","author":"PK Dash","year":"2010","unstructured":"Dash PK, Zhao J, Hergenroeder G, Moore AN. Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics. 2010;7(1):100\u201314.","journal-title":"Neurotherapeutics"},{"issue":"13","key":"4908_CR10","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2174\/138161206776843340","volume":"12","author":"N Marklund","year":"2006","unstructured":"Marklund N, Bakshi A, Castelbuono DJ, Conte V, McIntosh TK. Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr Pharm Des. 2006;12(13):1645\u201380.","journal-title":"Curr Pharm Des"},{"issue":"8","key":"4908_CR11","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1007\/s12035-018-1454-5","volume":"56","author":"X Ma","year":"2019","unstructured":"Ma X, Aravind A, Pfister BJ, Chandra N, Haorah J. Animal models of traumatic brain injury and assessment of injury severity. Mol Neurobiol. 2019;56(8):5332\u201345.","journal-title":"Mol Neurobiol"},{"issue":"8","key":"4908_CR12","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3390\/biology12081139","volume":"12","author":"MAM Freire","year":"2023","unstructured":"Freire MAM, Rocha GS, Bittencourt LO, Falcao D, Lima RR, Cavalcanti J. Cellular and molecular pathophysiology of traumatic brain injury: what have we learned so far? Biology. 2023;12(8):1139.","journal-title":"Biology"},{"issue":"8","key":"4908_CR13","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1089\/neu.2018.5990","volume":"36","author":"WB Hubbard","year":"2019","unstructured":"Hubbard WB, Joseph B, Spry M, Vekaria HJ, Saatman KE, Sullivan PG. Acute mitochondrial impairment underlies prolonged cellular dysfunction after repeated mild traumatic brain injuries. J Neurotrauma. 2019;36(8):1252\u201363.","journal-title":"J Neurotrauma"},{"key":"4908_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.expneurol.2015.05.009","volume":"271","author":"TJ Kilbaugh","year":"2015","unstructured":"Kilbaugh TJ, Karlsson M, Byro M, Bebee A, Ralston J, Sullivan S, et al. Mitochondrial bioenergetic alterations after focal traumatic brain injury in the immature brain. Exp Neurol. 2015;271:136\u201344.","journal-title":"Exp Neurol"},{"issue":"5","key":"4908_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/neu.2006.3673","volume":"24","author":"JD Pandya","year":"2007","unstructured":"Pandya JD, Pauly JR, Nukala VN, Sebastian AH, Day KM, Korde AS, et al. Post-injury administration of mitochondrial uncouplers increases tissue sparing and improves behavioral outcome following traumatic brain injury in rodents. J Neurotrauma. 2007;24(5):798\u2013811.","journal-title":"J Neurotrauma"},{"issue":"4","key":"4908_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/cne.20130","volume":"474","author":"PG Sullivan","year":"2004","unstructured":"Sullivan PG, Rabchevsky AG, Keller JN, Lovell M, Sodhi A, Hart RP, et al. Intrinsic differences in brain and spinal cord mitochondria: implication for therapeutic interventions. J Comp Neurol. 2004;474(4):524\u201334.","journal-title":"J Comp Neurol"},{"issue":"16","key":"4908_CR17","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1089\/neu.2020.7379","volume":"38","author":"JD Pandya","year":"2021","unstructured":"Pandya JD, Leung LY, Hwang HM, Yang X, Deng-Bryant Y, Shear DA. Time-course evaluation of brain regional mitochondrial bioenergetics in a pre-clinical model of severe penetrating traumatic brain injury. J Neurotrauma. 2021;38(16):2323\u201334.","journal-title":"J Neurotrauma"},{"issue":"1","key":"4908_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/mmr.2016.5974","volume":"15","author":"HT Zhang","year":"2017","unstructured":"Zhang HT, Zhang P, Gao Y, Li CL, Wang HJ, Chen LC, et al. Early VEGF inhibition attenuates blood-brain barrier disruption in ischemic rat brains by regulating the expression of MMPs. Mol Med Rep. 2017;15(1):57\u201364.","journal-title":"Mol Med Rep"},{"issue":"4","key":"4908_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1023\/B:JOBB.0000041766.71376.81","volume":"36","author":"G Fiskum","year":"2004","unstructured":"Fiskum G, Rosenthal RE, Vereczki V, Martin E, Hoffman GE, Chinopoulos C, et al. Protection against ischemic brain injury by inhibition of mitochondrial oxidative stress. J Bioenerg Biomembr. 2004;36(4):347\u201352.","journal-title":"J Bioenerg Biomembr"},{"issue":"4","key":"4908_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1476-5381.2012.02025.x","volume":"167","author":"G Cheng","year":"2012","unstructured":"Cheng G, Kong R, Lm Z, Jn Z. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. Br J Pharmacol. 2012;167(4):699\u2013719.","journal-title":"Br J Pharmacol"},{"key":"4908_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3389\/fneur.2019.00605","volume":"10","author":"JD Pandya","year":"2019","unstructured":"Pandya JD, Leung LY, Flerlage WJ, Gilsdorf JS, Bryant YD, Shear D. Comprehensive profile of acute mitochondrial dysfunction in a preclinical model of severe penetrating TBI. Front Neurol. 2019;10:605.","journal-title":"Front Neurol"},{"issue":"Pt B","key":"4908_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neuropharm.2018.07.014","volume":"145","author":"AM Lamade","year":"2019","unstructured":"Lamade AM, Kenny EM, Anthonymuthu TS, Soysal E, Clark RSB, Kagan VE, et al. Aiming for the target: Mitochondrial drug delivery in traumatic brain injury. Neuropharmacology. 2019;145(Pt B):209\u201319.","journal-title":"Neuropharmacology"},{"issue":"11","key":"4908_CR23","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959\u201372.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1\u20132","key":"4908_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","volume":"12","author":"WM Pardridge","year":"2007","unstructured":"Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12(1\u20132):54\u201361.","journal-title":"Drug Discov Today"},{"issue":"1","key":"4908_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1021\/cn200100h","volume":"3","author":"AK Ghose","year":"2012","unstructured":"Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem Neurosci. 2012;3(1):50\u201368.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"4908_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3\u201314.","journal-title":"NeuroRx"},{"issue":"8","key":"4908_CR27","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/molecules25081929","volume":"25","author":"SU Islam","year":"2020","unstructured":"Islam SU, Shehzad A, Ahmed MB, Lee YS. intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules. 2020;25(8):1929.","journal-title":"Molecules"},{"issue":"1","key":"4908_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2016.08.001","volume":"21","author":"OA Almazroo","year":"2017","unstructured":"Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis. 2017;21(1):1\u201320.","journal-title":"Clin Liver Dis"},{"issue":"6","key":"4908_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1365-2125.1994.tb04304.x","volume":"37","author":"GD Anderson","year":"1994","unstructured":"Anderson GD, Gidal BE, Hendryx RJ, Awan AB, Temkin NR, Wilensky AJ, et al. Decreased plasma protein binding of valproate in patients with acute head trauma. Br J Clin Pharmacol. 1994;37(6):559\u201362.","journal-title":"Br J Clin Pharmacol"},{"key":"4908_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11481-006-9039-x","volume":"2","author":"LR Hanson","year":"2007","unstructured":"Hanson LR, Frey WH. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol. 2007;2:81\u20136.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1\u20132","key":"4908_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0022-510X(01)00532-9","volume":"187","author":"XF Liu","year":"2001","unstructured":"Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH 2nd. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci. 2001;187(1\u20132):91\u20137.","journal-title":"J Neurol Sci"},{"issue":"2","key":"4908_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","volume":"127","author":"RG Thorne","year":"2004","unstructured":"Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127(2):481\u201396.","journal-title":"Neuroscience"},{"issue":"1\u20132","key":"4908_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jneuroim.2004.02.011","volume":"151","author":"TM Ross","year":"2004","unstructured":"Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH 2nd. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol. 2004;151(1\u20132):66\u201377.","journal-title":"J Neuroimmunol"},{"issue":"6","key":"4908_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejcb.2009.02.001","volume":"88","author":"L Danielyan","year":"2009","unstructured":"Danielyan L, Sch\u00e4fer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, et al. Intranasal delivery of cells to the brain. Eur J Cell Biol. 2009;88(6):315\u201324.","journal-title":"Eur J Cell Biol"},{"issue":"1","key":"4908_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2337\/db10-0329","volume":"60","author":"C Benedict","year":"2011","unstructured":"Benedict C, Brede S, Schi\u00f6th HB, Lehnert H, Schultes B, Born J, et al. Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men. Diabetes. 2011;60(1):114\u20138.","journal-title":"Diabetes"},{"issue":"7","key":"4908_CR36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","volume":"27","author":"J Freiherr","year":"2013","unstructured":"Freiherr J, Hallschmid M, Frey WH 2nd, Br\u00fcnner YF, Chapman CD, H\u00f6lscher C, et al. Intranasal insulin as a treatment for Alzheimer\u2019s disease: a review of basic research and clinical evidence. CNS Drugs. 2013;27(7):505\u201314.","journal-title":"CNS Drugs"},{"key":"4908_CR37","doi-asserted-by":"publisher","DOI":"10.3791\/4440","author":"LR Hanson","year":"2013","unstructured":"Hanson LR, Fine JM, Svitak AL, Faltesek KA. Intranasal administration of CNS therapeutics to awake mice. J Vis Exp. 2013. https:\/\/doi.org\/10.3791\/4440.","journal-title":"J Vis Exp"},{"issue":"10","key":"4908_CR38","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","volume":"30","author":"CD Chapman","year":"2013","unstructured":"Chapman CD, Frey WH, Craft S, Danielyan L, Hallschmid M, Schi\u00f6th HB, et al. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res. 2013;30(10):2475\u201384.","journal-title":"Pharm Res"},{"issue":"8","key":"4908_CR39","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.psyneuen.2011.02.015","volume":"36","author":"E MacDonald","year":"2011","unstructured":"MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011;36(8):1114\u201326.","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"4908_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12016-010-8206-2","volume":"41","author":"RA Nathan","year":"2011","unstructured":"Nathan RA. Intranasal steroids in the treatment of allergy-induced rhinorrhea. Clin Rev Allergy Immunol. 2011;41(1):89\u2013101.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"4908_CR41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1210\/jc.2011-1802","volume":"97","author":"E Shemesh","year":"2012","unstructured":"Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab. 2012;97(2):366\u201376.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4908_CR42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ajem.2005.11.004","volume":"24","author":"TR Wolfe","year":"2006","unstructured":"Wolfe TR, Macfarlane TC. Intranasal midazolam therapy for pediatric status epilepticus. Am J Emerg Med. 2006;24(3):343\u20136.","journal-title":"Am J Emerg Med"},{"issue":"1","key":"4908_CR43","first-page":"137","volume":"30","author":"TS Reese","year":"1971","unstructured":"Reese TS, Feder N, Brightman MW. Electron microscopic study of the blood-brain and blood-cerebrospinal fluid barriers with microperoxidase. J Neuropathol Exp Neurol. 1971;30(1):137\u20138.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"4908_CR44","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","volume":"23","author":"R Nau","year":"2010","unstructured":"Nau R, S\u00f6rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858\u201383.","journal-title":"Clin Microbiol Rev"},{"key":"4908_CR45","doi-asserted-by":"publisher","DOI":"10.1201\/b18959-5","author":"L Price","year":"2016","unstructured":"Price L, Wilson C, Grant G. Blood\u2013brain barrier pathophysiology following traumatic brain injury. Transl Res Trauma Brain Injury. 2016. https:\/\/doi.org\/10.1201\/b18959-5.","journal-title":"Transl Res Trauma Brain Injury"},{"key":"4908_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/3-211-30714-1_38","volume":"96","author":"A Beaumont","year":"2006","unstructured":"Beaumont A, Fatouros P, Gennarelli T, Corwin F, Marmarou A. Bolus tracer delivery measured by MRI confirms edema without blood-brain barrier permeability in diffuse traumatic brain injury. Acta Neurochir Suppl. 2006;96:171\u20134.","journal-title":"Acta Neurochir Suppl"},{"issue":"6","key":"4908_CR47","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3171\/jns.1996.85.6.1113","volume":"85","author":"P Barz\u00f3","year":"1996","unstructured":"Barz\u00f3 P, Marmarou A, Fatouros P, Corwin F, Dunbar J. Magnetic resonance imaging-monitored acute blood-brain barrier changes in experimental traumatic brain injury. J Neurosurg. 1996;85(6):1113\u201321.","journal-title":"J Neurosurg"},{"issue":"2","key":"4908_CR48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/neu.2011.2053","volume":"29","author":"NE Lopez","year":"2012","unstructured":"Lopez NE, Krzyzaniak MJ, Blow C, Putnam J, Ortiz-Pomales Y, Hageny AM, et al. Ghrelin prevents disruption of the blood-brain barrier after traumatic brain injury. J Neurotrauma. 2012;29(2):385\u201393.","journal-title":"J Neurotrauma"},{"key":"4908_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.brainres.2012.11.028","volume":"1493","author":"Q Lv","year":"2013","unstructured":"Lv Q, Fan X, Xu G, Liu Q, Tian L, Cai X, et al. Intranasal delivery of nerve growth factor attenuates aquaporins-4-induced edema following traumatic brain injury in rats. Brain Res. 2013;1493:80\u20139.","journal-title":"Brain Res"},{"issue":"4","key":"4908_CR50","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12975-011-0125-x","volume":"2","author":"A Chodobski","year":"2011","unstructured":"Chodobski A, Zink BJ, Szmydynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res. 2011;2(4):492\u2013516.","journal-title":"Transl Stroke Res"},{"issue":"161","key":"4908_CR51","doi-asserted-by":"publisher","first-page":"161ra50","DOI":"10.1126\/scitranslmed.3004660","volume":"4","author":"T Menge","year":"2012","unstructured":"Menge T, Zhao Y, Zhao J, Wataha K, Gerber M, Zhang J, et al. Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Sci Transl Med. 2012;4(161):161ra50.","journal-title":"Sci Transl Med."},{"issue":"17","key":"4908_CR52","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1089\/neu.2017.5271","volume":"35","author":"J Chen","year":"2018","unstructured":"Chen J, Hu J, Liu H, Xiong Y, Zou Y, Huang W, et al. FGF21 protects the blood-brain barrier by upregulating PPAR\u03b3 via FGFR1\/\u03b2-klotho after traumatic brain injury. J Neurotrauma. 2018;35(17):2091\u2013103.","journal-title":"J Neurotrauma"},{"issue":"6","key":"4908_CR53","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1161\/STROKEAHA.115.009099","volume":"46","author":"DN Doll","year":"2015","unstructured":"Doll DN, Hu H, Sun J, Lewis SE, Simpkins JW, Ren X. Mitochondrial crisis in cerebrovascular endothelial cells opens the blood-brain barrier. Stroke. 2015;46(6):1681\u20139.","journal-title":"Stroke"},{"issue":"1","key":"4908_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/187221109787158355","volume":"3","author":"SA Pathan","year":"2009","unstructured":"Pathan SA, Iqbal Z, Zaidi S, Talegaonkar S, Vohra D, Jain GK, et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul. 2009;3(1):71\u201389.","journal-title":"Recent Pat Drug Deliv Formul"},{"issue":"1","key":"4908_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1018911206646","volume":"9","author":"MA Sarkar","year":"1992","unstructured":"Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res. 1992;9(1):1\u20139.","journal-title":"Pharm Res"},{"key":"4908_CR56","first-page":"25","volume":"1","author":"DT Manallack","year":"2007","unstructured":"Manallack DT. The pK(a) distribution of drugs: application to drug discovery. Perspect Med Chem. 2007;1:25\u201338.","journal-title":"Perspect Med Chem"},{"key":"4908_CR57","first-page":"247","volume-title":"Regulatory aspects of nasal and pulmonary spray drug products","author":"DJ Farina","year":"2010","unstructured":"Farina DJ. Regulatory aspects of nasal and pulmonary spray drug products. Handbook of Non-invasive drug delivery systems: Elsevier; 2010. p. 247\u201390."},{"key":"4908_CR58","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.2741\/2267","volume":"12","author":"W Ying","year":"2007","unstructured":"Ying W, Wei G, Wang D, Wang Q, Tang X, Shi J, et al. Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia. Front Biosci. 2007;12:2728\u201334.","journal-title":"Front Biosci"},{"issue":"6","key":"4908_CR59","first-page":"2345","volume":"34","author":"E Maffezzoni","year":"2020","unstructured":"Maffezzoni E, Notargiacomo M, Agostini S, Gelardi M. Efficacy of a nasal spray containing N-acetylcysteine in hypertonic solution in the treatment of nonallergic chronic rhinitis with goblet cell metaplasia. J Biol Regul Homeost Agents. 2020;34(6):2345\u201352.","journal-title":"J Biol Regul Homeost Agents"},{"key":"4908_CR60","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fneur.2017.00219","volume":"8","author":"U Kawoos","year":"2017","unstructured":"Kawoos U, McCarron RM, Chavko M. Protective effect of N-acetylcysteine amide on blast-induced increase in intracranial pressure in rats. Front Neurol. 2017;8:219.","journal-title":"Front Neurol"},{"issue":"8","key":"4908_CR61","doi-asserted-by":"publisher","first-page":"14487","DOI":"10.3390\/molecules200814487","volume":"20","author":"DN Silachev","year":"2015","unstructured":"Silachev DN, Plotnikov EY, Zorova LD, Pevzner IB, Sumbatyan NV, Korshunova GA, et al. Neuroprotective effects of mitochondria-targeted plastoquinone and thymoquinone in a rat model of brain ischemia\/reperfusion injury. Molecules. 2015;20(8):14487\u2013503.","journal-title":"Molecules"},{"issue":"4","key":"4908_CR62","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1211\/jpp.59.4.0004","volume":"59","author":"Y Li","year":"2007","unstructured":"Li Y, Fawcett JP, Zhang H, Tucker IG. Transport and metabolism of MitoQ10, a mitochondria-targeted antioxidant, in Caco-2 cell monolayers. J Pharm Pharmacol. 2007;59(4):503\u201311.","journal-title":"J Pharm Pharmacol"},{"key":"4908_CR63","doi-asserted-by":"publisher","first-page":"29753","DOI":"10.1038\/srep29753","volume":"6","author":"C Guo","year":"2016","unstructured":"Guo C, Li M, Qi X, Lin G, Cui F, Li F, et al. Intranasal delivery of nanomicelle curcumin promotes corneal epithelial wound healing in streptozotocin-induced diabetic mice. Sci Rep. 2016;6:29753.","journal-title":"Sci Rep"},{"key":"4908_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.phymed.2018.06.022","volume":"51","author":"PS Chauhan","year":"2018","unstructured":"Chauhan PS, Singh DK, Dash D, Singh R. Intranasal curcumin regulates chronic asthma in mice by modulating NF-\u0138B activation and MAPK signaling. Phytomedicine. 2018;51:29\u201338.","journal-title":"Phytomedicine"},{"issue":"6","key":"4908_CR65","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/jphp.12043","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen X, Zhi F, Jia X, Zhang X, Ambardekar R, Meng Z, et al. Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel. J Pharm Pharmacol. 2013;65(6):807\u201316.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"4908_CR66","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cyto.2015.07.022","volume":"76","author":"A Kumari","year":"2015","unstructured":"Kumari A, Dash D, Singh R. Lipopolysaccharide (LPS) exposure differently affects allergic asthma exacerbations and its amelioration by intranasal curcumin in mice. Cytokine. 2015;76(2):334\u201342.","journal-title":"Cytokine"},{"issue":"3","key":"4908_CR67","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s10753-014-0076-y","volume":"38","author":"A Kumari","year":"2015","unstructured":"Kumari A, Tyagi N, Dash D, Singh R. Intranasal curcumin ameliorates lipopolysaccharide-induced acute lung injury in mice. Inflammation. 2015;38(3):1103\u201312.","journal-title":"Inflammation"},{"issue":"10","key":"4908_CR68","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/mt.2011.164","volume":"19","author":"X Zhuang","year":"2011","unstructured":"Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther. 2011;19(10):1769\u201379.","journal-title":"Mol Ther"},{"issue":"1","key":"4908_CR69","doi-asserted-by":"publisher","first-page":"14257","DOI":"10.1038\/s41598-018-32423-0","volume":"8","author":"A Monteillier","year":"2018","unstructured":"Monteillier A, Voisin A, Furrer P, All\u00e9mann E, Cuendet M. Intranasal administration of resveratrol successfully prevents lung cancer in A\/J mice. Sci Rep. 2018;8(1):14257.","journal-title":"Sci Rep"},{"key":"4908_CR70","unstructured":"Shamsher E, Sulaimankutty R, Dine K, Luong V, Davis B, Willett K, et al. Intranasal delivery of resveratrol nanoparticles reduces retinal ganglion cell loss in a model of multiple sclerosis. 2020;61(7):2476"},{"issue":"6","key":"4908_CR71","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.bbadis.2014.09.011","volume":"1852","author":"S Bastianetto","year":"2015","unstructured":"Bastianetto S, M\u00e9nard C, Quirion R. Neuroprotective action of resveratrol. Biochim Biophys Acta Mol Basis Dis. 2015;1852(6):1195\u2013201.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"4908_CR72","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/JES.0b013e3182141f80","volume":"39","author":"Z Ungvari","year":"2011","unstructured":"Ungvari Z, Sonntag WE, de Cabo R, Baur JA, Csiszar A. Mitochondrial protection by resveratrol. Exerc Sport Sci Rev. 2011;39(3):128.","journal-title":"Exerc Sport Sci Rev"},{"issue":"8","key":"4908_CR73","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00210-021-02096-0","volume":"394","author":"SKL Rompicherla","year":"2021","unstructured":"Rompicherla SKL, Arumugam K, Bojja SL, Kumar N, Rao CM. Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(8):1737\u201355.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"21","key":"4908_CR74","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.3390\/ma14216291","volume":"14","author":"M Bhanderi","year":"2021","unstructured":"Bhanderi M, Shah J, Gorain B, Nair AB, Jacob S, Asdaq SMB, et al. Optimized rivastigmine nanoparticles coated with eudragit for intranasal application to brain delivery: evaluation and nasal ciliotoxicity studies. Materials. 2021;14(21):6291.","journal-title":"Materials"},{"key":"4908_CR75","unstructured":"EXELON. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/21025lbl.pdf."},{"key":"4908_CR76","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2147\/CIA.S129145","volume":"12","author":"N Kandiah","year":"2017","unstructured":"Kandiah N, Pai MC, Senanarong V, Looi I, Ampil E, Park KW, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson\u2019s disease dementia. Clin Interv Aging. 2017;12:697\u2013707.","journal-title":"Clin Interv Aging"},{"key":"4908_CR77","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.nbd.2018.07.010","volume":"118","author":"P Saha","year":"2018","unstructured":"Saha P, Gupta R, Sen T, Sen N. Activation of cyclin D1 affects mitochondrial mass following traumatic brain injury. Neurobiol Dis. 2018;118:108\u201316.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"4908_CR78","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/MCB.06570-11","volume":"32","author":"T Kanie","year":"2012","unstructured":"Kanie T, Onoyama I, Matsumoto A, Yamada M, Nakatsumi H, Tateishi Y, et al. Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation. Mol Cell Biol. 2012;32(3):590\u2013605.","journal-title":"Mol Cell Biol"},{"key":"4908_CR79","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.lfs.2018.09.025","volume":"211","author":"A Iqubal","year":"2018","unstructured":"Iqubal A, Sharma S, Sharma K, Bhavsar A, Hussain I, Iqubal MK, et al. Intranasally administered pitavastatin ameliorates pentylenetetrazol-induced neuroinflammation, oxidative stress and cognitive dysfunction. Life Sci. 2018;211:172\u201381.","journal-title":"Life Sci"},{"key":"4908_CR80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.yebeh.2017.07.004","volume":"75","author":"MU Ashhar","year":"2017","unstructured":"Ashhar MU, Ahmad MZ, Jain V, Agarwal NB, Ahmad FJ, Jain GK. Intranasal pitavastatin attenuates seizures in different experimental models of epilepsy in mice. Epilepsy Behav. 2017;75:56\u20139.","journal-title":"Epilepsy Behav"},{"key":"4908_CR81","unstructured":"Livalo. https:\/\/www.rxlist.com\/livalo-side-effects-drug-center.htm."},{"issue":"2","key":"4908_CR82","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1179\/1743132812Y.0000000127","volume":"35","author":"T Kurata","year":"2013","unstructured":"Kurata T, Miyazaki K, Morimoto N, Kawai H, Ohta Y, Ikeda Y, et al. Atorvastatin and pitavastatin reduce oxidative stress and improve IR\/LDL-R signals in Alzheimer\u2019s disease. Neurol Res. 2013;35(2):193\u2013205.","journal-title":"Neurol Res"},{"issue":"3","key":"4908_CR83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3466.2003.tb00116.x","volume":"21","author":"K Kajinami","year":"2003","unstructured":"Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003;21(3):199\u2013215.","journal-title":"Cardiovasc Drug Rev"},{"issue":"7","key":"4908_CR84","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1007\/s12035-016-0034-9","volume":"54","author":"N Zhao","year":"2017","unstructured":"Zhao N, Zhuo X, Lu Y, Dong Y, Ahmed ME, Tucker D, et al. Intranasal delivery of a caspase-1 inhibitor in the treatment of global cerebral ischemia. Mol Neurobiol. 2017;54(7):4936\u201352.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"4908_CR85","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/genes11020131","volume":"11","author":"RH Pirzada","year":"2020","unstructured":"Pirzada RH, Javaid N, Choi S. The roles of the NLRP3 inflammasome in neurodegenerative and metabolic diseases and in relevant advanced therapeutic interventions. Genes. 2020;11(2):131.","journal-title":"Genes"},{"issue":"2","key":"4908_CR86","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/aps.2016.130","volume":"38","author":"H Yang","year":"2017","unstructured":"Yang H, Gu Z-T, Li L, Maegele M, Zhou B-Y, Li F, et al. SIRT1 plays a neuroprotective role in traumatic brain injury in rats via inhibiting the p38 MAPK pathway. Acta Pharmacol Sinica. 2017;38(2):168\u201381.","journal-title":"Acta Pharmacol Sinica"},{"issue":"3","key":"4908_CR87","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/pharmaceutics11030118","volume":"11","author":"T Musumeci","year":"2019","unstructured":"Musumeci T, Bonaccorso A, Puglisi G. Epilepsy disease and nose-to-brain delivery of polymeric nanoparticles: an overview. Pharmaceutics. 2019;11(3):118.","journal-title":"Pharmaceutics"},{"key":"4908_CR88","unstructured":"PENTOXIFYLLINE. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=7096593b-0054-4d51-83df-0208ccdcc147&type=display."},{"key":"4908_CR89","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7908072","author":"Y Kang","year":"2017","unstructured":"Kang Y, Yan W, Fang H, Zhang G, Du Y, Wang L, et al. Alleviation of oxidative damage and involvement of Nrf2-ARE pathway in mesodopaminergic system and hippocampus of status epilepticus rats pretreated by intranasal pentoxifylline. Oxid Med Cell Longev. 2017. https:\/\/doi.org\/10.1155\/2017\/7908072.","journal-title":"Oxid Med Cell Longev"},{"key":"4908_CR90","unstructured":"Pentoxifylline. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Pentoxifylline."},{"key":"4908_CR91","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jpsychires.2019.02.003","volume":"112","author":"V Naidoo","year":"2019","unstructured":"Naidoo V, Mdanda S, Ntshangase S, Naicker T, Kruger HG, Govender T, et al. Brain penetration of ketamine: Intranasal delivery VS parenteral routes of administraion. J Psychiatr Res. 2019;112:7\u201311.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"4908_CR92","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1046\/j.1442-2026.2003.00433.x","volume":"15","author":"A Cromhout","year":"2003","unstructured":"Cromhout A. Ketamine: its use in the emergency department. Emerg Med. 2003;15(2):155\u20139.","journal-title":"Emerg Med"},{"key":"4908_CR93","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2147\/DDDT.S160046","volume":"12","author":"J Liang","year":"2018","unstructured":"Liang J, Wu S, Xie W, He H. Ketamine ameliorates oxidative stress-induced apoptosis in experimental traumatic brain injury via the Nrf2 pathway. Drug Des Devel Ther. 2018;12:845\u201353.","journal-title":"Drug Des Devel Ther"},{"key":"4908_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119384","volume":"583","author":"L Zhang","year":"2020","unstructured":"Zhang L, Pang L, Zhu S, Ma J, Li R, Liu Y, et al. Intranasal tetrandrine temperature-sensitive in situ hydrogels for the treatment of microwave-induced brain injury. Int J Pharm. 2020;583: 119384.","journal-title":"Int J Pharm"},{"issue":"3","key":"4908_CR95","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/030089161009600314","volume":"96","author":"M Xu","year":"2010","unstructured":"Xu M, Sheng L, Zhu X, Zeng S, Chi D, Zhang G-J. Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats. Tumori J. 2010;96(3):460\u20134.","journal-title":"Tumori J"},{"issue":"3","key":"4908_CR96","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JAD-150307","volume":"47","author":"TS Salameh","year":"2015","unstructured":"Salameh TS, Bullock KM, Hujoel IA, Niehoff ML, Wolden-Hanson T, Kim J, et al. Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J Alzheimers Dis. 2015;47(3):715\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"4908_CR97","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12975-015-0409-7","volume":"6","author":"V-A Lioutas","year":"2015","unstructured":"Lioutas V-A, Alfaro-Martinez F, Bedoya F, Chung C-C, Pimentel DA, Novak V. Intranasal insulin and insulin-like growth factor 1 as neuroprotectants in acute ischemic stroke. Transl Stroke Res. 2015;6(4):264\u201375.","journal-title":"Transl Stroke Res"},{"issue":"3","key":"4908_CR98","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1096\/fj.201802043R","volume":"33","author":"GN Ruegsegger","year":"2019","unstructured":"Ruegsegger GN, Manjunatha S, Summer P, Gopala S, Zabeilski P, Dasari S, et al. Insulin deficiency and intranasal insulin alter brain mitochondrial function: a potential factor for dementia in diabetes. FASEB J. 2019;33(3):4458\u201372.","journal-title":"FASEB J"},{"issue":"4","key":"4908_CR99","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","volume":"29","author":"C H\u00f6lscher","year":"2020","unstructured":"H\u00f6lscher C. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opin Investig Drugs. 2020;29(4):333\u201348.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"4908_CR100","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EC-14-0092","volume":"4","author":"MK Montgomery","year":"2015","unstructured":"Montgomery MK, Turner N. Mitochondrial dysfunction and insulin resistance: an update. Endocr Connect. 2015;4(1):R1\u201315.","journal-title":"Endocr Connect"},{"issue":"1","key":"4908_CR101","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/pharmaceutics12010076","volume":"12","author":"S Ms","year":"2020","unstructured":"Ms S, Ms N, Mmi B, Me-S M, Mae-H S. Novel intranasal drug delivery: geraniol charged polymeric mixed micelles for targeting cerebral insult as a result of ischaemia\/reperfusion. Pharmaceutics. 2020;12(1):76.","journal-title":"Pharmaceutics"},{"key":"4908_CR102","volume-title":"The science and practice of pharmacy","author":"JP Remington","year":"2006","unstructured":"Remington JP. The science and practice of pharmacy. Philadelphia: Lippincott Williams & Wilkins; 2006."},{"issue":"1","key":"4908_CR103","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/pharmaceutics12010076","volume":"12","author":"MS Soliman","year":"2020","unstructured":"Soliman MS, Sheta MN, Ibrahim MMB, El-Shawwa MM, Abd El-Halim MS. Novel intranasal drug delivery: geraniol charged polymeric mixed micelles for targeting cerebral insult as a result of ischaemia\/reperfusion. Pharmaceutics. 2020;12(1):76.","journal-title":"Pharmaceutics"},{"issue":"10","key":"4908_CR104","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s11064-018-2617-5","volume":"43","author":"KR Rekha","year":"2018","unstructured":"Rekha KR, Sivakamasundari RI. Geraniol protects against the protein and oxidative stress induced by rotenone in an in vitro model of Parkinson\u2019s disease. Neurochem Res. 2018;43(10):1947\u201362.","journal-title":"Neurochem Res"},{"issue":"5","key":"4908_CR105","first-page":"5902","volume":"12","author":"T Jiang","year":"2019","unstructured":"Jiang T, Huang L, Zhang X, Liang XJIJCEM. Nasal administration of muscone promotes cAMP-PKA-CREB signaling in rats with traumatic brain injury. Int J Clin Exp Med. 2019;12(5):5902\u20138.","journal-title":"Int J Clin Exp Med"},{"key":"4908_CR106","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15011","author":"Z Ly","year":"2020","unstructured":"Ly Z, Yao M, Zr T, Sf L, Yj S, Ye J, et al. Muscone suppresses inflammatory responses and neuronal damage in a rat model of cervical spondylotic myelopathy by regulating Drp1-dependent mitochondrial fission. J Neurochem. 2020. https:\/\/doi.org\/10.1111\/jnc.15011.","journal-title":"J Neurochem"},{"issue":"5","key":"4908_CR107","first-page":"5902","volume":"12","author":"T Jiang","year":"2019","unstructured":"Jiang T, Huang L, Zhang X, Liang X. Nasal administration of muscone promotes cAMP-PKA-CREB signaling in rats with traumatic brain injury. Int J Clin Exp Med. 2019;12(5):5902\u20138.","journal-title":"Int J Clin Exp Med"},{"issue":"7","key":"4908_CR108","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol. 2014;13(7):676\u201385.","journal-title":"Lancet Neurol"},{"issue":"5","key":"4908_CR109","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.65","volume":"2","author":"I Magen","year":"2014","unstructured":"Magen I, Ostritsky R, Richter F, Zhu C, Fleming SM, Lemesre V, et al. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing \u03b1-synuclein. Pharmacol Res Perspect. 2014;2(5): e00065.","journal-title":"Pharmacol Res Perspect"},{"key":"4908_CR110","unstructured":"Davunetide. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/9832404#section=Pharmacology-and-Biochemistry."},{"issue":"4","key":"4908_CR111","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3109\/10715762.2015.1011153","volume":"49","author":"A Arya","year":"2015","unstructured":"Arya A, Meena R, Sethy NK, Das M, Sharma M, Bhargava K. NAP (davunetide) protects primary hippocampus culture by modulating expression profile of antioxidant genes during limiting oxygen conditions. Free Radic Res. 2015;49(4):440\u201352.","journal-title":"Free Radic Res"},{"key":"4908_CR112","first-page":"85","volume":"8","author":"M Gold","year":"2012","unstructured":"Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat. 2012;8:85.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"4908_CR113","doi-asserted-by":"publisher","DOI":"10.1177\/1759091415605114","author":"D Chen","year":"2015","unstructured":"Chen D, Lee J, Gu X, Wei L, Yu SP. Intranasal delivery of Apelin-13 Is neuroprotective and promotes angiogenesis after ischemic stroke in mice. ASN Neuro. 2015. https:\/\/doi.org\/10.1177\/1759091415605114.","journal-title":"ASN Neuro"},{"issue":"3","key":"4908_CR114","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.scr.2011.12.004","volume":"8","author":"X Zeng","year":"2012","unstructured":"Zeng X, Yu SP, Taylor T, Ogle M, Wei L. Protective effect of apelin on cultured rat bone marrow mesenchymal stem cells against apoptosis. Stem Cell Res. 2012;8(3):357\u201367.","journal-title":"Stem Cell Res"},{"issue":"4","key":"4908_CR115","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/21691401.2017.1337024","volume":"46","author":"N Ahmad","year":"2018","unstructured":"Ahmad N, Ahmad R, Naqvi AA, Alam MA, Ashafaq M, Abdur Rub R, et al. Intranasal delivery of quercetin-loaded mucoadhesive nanoemulsion for treatment of cerebral ischaemia. Artif Cells Nanomed Biotechnol. 2018;46(4):717\u201329.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"12","key":"4908_CR116","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/CM9.0000000000000289","volume":"132","author":"X-Q Chen","year":"2019","unstructured":"Chen X-Q, Qiu K, Liu H, He Q, Bai J-H, Lu W. Application and prospects of butylphthalide for the treatment of neurologic diseases. Chin Med J. 2019;132(12):1467.","journal-title":"Chin Med J"},{"issue":"7","key":"4908_CR117","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.14336\/AD.2020.1226","volume":"12","author":"ZZ Wei","year":"2021","unstructured":"Wei ZZ, Chen D, Lee MJH, Zhao Y, Gu X, Yu SP, et al. DL-3-n-butylphthalide increases collateriogenesis and functional recovery after focal ischemic stroke in mice. Aging Dis. 2021;12(7):1835\u201349.","journal-title":"Aging Dis"},{"key":"4908_CR118","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.2741\/2443","volume":"12","author":"G Wei","year":"2007","unstructured":"Wei G, Wang D, Lu H, Parmentier S, Wang Q, Panter SS, et al. Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury. Front Biosci. 2007;12:4986\u201396.","journal-title":"Front Biosci"},{"issue":"2\u20133","key":"4908_CR119","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejphar.2010.05.033","volume":"641","author":"N Ducharme","year":"2010","unstructured":"Ducharme N, Banks WA, Morley JE, Robinson SM, Niehoff ML, Mattern C, et al. Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. Eur J Pharmacol. 2010;641(2\u20133):128\u201334.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"4908_CR120","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/13697137.2018.1463982","volume":"21","author":"R Sitruk-Ware","year":"2018","unstructured":"Sitruk-Ware R. Non-clinical studies of progesterone. Climacteric. 2018;21(4):315\u201320.","journal-title":"Climacteric"},{"issue":"6","key":"4908_CR121","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1210\/en.2007-1227","volume":"149","author":"RW Irwin","year":"2008","unstructured":"Irwin RW, Yao J, Hamilton RT, Cadenas E, Brinton RD, Nilsen J. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology. 2008;149(6):3167\u201375.","journal-title":"Endocrinology"},{"key":"4908_CR122","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/IJN.S151474","volume":"13","author":"Q Meng","year":"2018","unstructured":"Meng Q, Wang A, Hua H, Jiang Y, Wang Y, Mu H, et al. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease. Int J Nanomedicine. 2018;13:705\u201318.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"4908_CR123","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1745-7254.2007.00486.x","volume":"28","author":"Y Zhao","year":"2007","unstructured":"Zhao Y, Yue P, Tao T, Chen QH. Drug brain distribution following intranasal administration of Huperzine A in situ gel in rats. Acta Pharmacol Sin. 2007;28(2):273\u20138.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"4908_CR124","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF03191002","volume":"32","author":"Y Li","year":"2007","unstructured":"Li Y, Zhang R, Li C, Jiang X. Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet. 2007;32(4):183\u20137.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1\u20133","key":"4908_CR125","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0014-5793(02)03107-1","volume":"526","author":"J Zhou","year":"2002","unstructured":"Zhou J, Tang XC. Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett. 2002;526(1\u20133):21\u20135.","journal-title":"FEBS Lett"},{"issue":"11","key":"4908_CR126","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1248\/bpb.31.2024","volume":"31","author":"W Tang","year":"2008","unstructured":"Tang W, Zhang Y, Gao J, Ding X, Gao S. The anti-fatigue effect of 20(R)-ginsenoside Rg3 in mice by intranasally administration. Biol Pharm Bull. 2008;31(11):2024\u20137.","journal-title":"Biol Pharm Bull"},{"issue":"1\u20132","key":"4908_CR127","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jchromb.2004.11.036","volume":"816","author":"T Qian","year":"2005","unstructured":"Qian T, Cai Z, Wong RN, Mak NK, Jiang Z-H. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B. 2005;816(1\u20132):223\u201332.","journal-title":"J Chromatogr B"},{"issue":"S2","key":"4908_CR128","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jcp.1040860509","volume":"86","author":"G Elliott","year":"1975","unstructured":"Elliott G, Rechsteiner M. Pyridine nucleotide metabolism in mitotic cells. J Cell Physiol. 1975;86(S2):641\u201351.","journal-title":"J Cell Physiol"},{"issue":"1","key":"4908_CR129","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41598-017-00851-z","volume":"7","author":"CC Wei","year":"2017","unstructured":"Wei CC, Kong YY, Li GQ, Guan YF, Wang P, Miao CY. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2\/HO-1 signaling pathway. Sci Rep. 2017;7(1):717.","journal-title":"Sci Rep"},{"key":"4908_CR130","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.expneurol.2014.04.020","volume":"257","author":"JD Pandya","year":"2014","unstructured":"Pandya JD, Readnower RD, Patel SP, Yonutas HM, Pauly JR, Goldstein GA, et al. N-acetylcysteine amide confers neuroprotection, improves bioenergetics and behavioral outcome following TBI. Exp Neurol. 2014;257:106\u201313.","journal-title":"Exp Neurol"},{"issue":"2","key":"4908_CR131","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jcph.1008","volume":"58","author":"LD Coles","year":"2018","unstructured":"Coles LD, Tuite PJ, \u00d6z G, Mishra UR, Kartha RV, Sullivan KM, et al. Repeated-dose oral N-acetylcysteine in Parkinson\u2019s disease: pharmacokinetics and effect on brain glutathione and oxidative stress. J Clin Pharmacol. 2018;58(2):158\u201367.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4908_CR132","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3233\/JPD-161040","volume":"7","author":"LK Mischley","year":"2017","unstructured":"Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb study of intranasal glutathione in Parkinson\u2019s disease. J Parkinsons Dis. 2017;7(2):289\u201399.","journal-title":"J Parkinsons Dis"},{"issue":"11","key":"4908_CR133","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.18632\/aging.101054","volume":"8","author":"NA Stefanova","year":"2016","unstructured":"Stefanova NA, Muraleva NA, Maksimova KY, Rudnitskaya EA, Kiseleva E, Telegina DV, et al. An antioxidant specifically targeting mitochondria delays progression of Alzheimer\u2019s disease-like pathology. Aging. 2016;8(11):2713\u201333.","journal-title":"Aging"},{"issue":"9","key":"4908_CR134","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.bbadis.2018.05.018","volume":"1864","author":"Y Xi","year":"2018","unstructured":"Xi Y, Feng D, Tao K, Wang R, Shi Y, Qin H, et al. MitoQ protects dopaminergic neurons in a 6-OHDA induced PD model by enhancing Mfn2-dependent mitochondrial fusion via activation of PGC-1\u03b1. Biochim Biophys Acta Mol Basis Dis. 2018;1864(9):2859\u201370.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"44","key":"4908_CR135","doi-asserted-by":"publisher","first-page":"15703","DOI":"10.1523\/JNEUROSCI.0552-11.2011","volume":"31","author":"MJ McManus","year":"2011","unstructured":"McManus MJ, Murphy MP, Franklin JL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer\u2019s disease. J Neurosci. 2011;31(44):15703\u201315.","journal-title":"J Neurosci"},{"issue":"2","key":"4908_CR136","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/biomedicines10020250","volume":"10","author":"MA Haidar","year":"2022","unstructured":"Haidar MA, Shakkour Z, Barsa C, Tabet M, Mekhjian S, Darwish H, et al. Mitoquinone helps combat the neurological, cognitive, and molecular consequences of open head traumatic brain injury at chronic time point. Biomedicines. 2022;10(2):250.","journal-title":"Biomedicines"},{"key":"4908_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.113987","volume":"351","author":"M Tabet","year":"2022","unstructured":"Tabet M, El-Kurdi M, Haidar MA, Nasrallah L, Reslan MA, Shear D, et al. Mitoquinone supplementation alleviates oxidative stress and pathologic outcomes following repetitive mild traumatic brain injury at a chronic time point. Exp Neurol. 2022;351: 113987.","journal-title":"Exp Neurol"},{"issue":"6","key":"4908_CR138","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/HYPERTENSIONAHA.117.10787","volume":"71","author":"MJ Rossman","year":"2018","unstructured":"Rossman MJ, Santos-Parker JR, Steward CA, Bispham NZ, Cuevas LM, Rosenberg HL, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018;71(6):1056\u201363.","journal-title":"Hypertension"},{"issue":"4","key":"4908_CR139","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1553-7250(14)40021-7","volume":"40","author":"RM Speck","year":"2014","unstructured":"Speck RM, Foster JJ, Mulhern VA, Burke SV, Sullivan PG, Fleisher LA. Development of a professionalism committee approach to address unprofessional medical staff behavior at an academic medical center. Joint Comm J Quality Patient Safety. 2014;40(4):161\u20137.","journal-title":"Joint Comm J Quality Patient Safety"},{"issue":"3","key":"4908_CR140","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1440-1681.2011.05648.x","volume":"39","author":"SC Gupta","year":"2012","unstructured":"Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39(3):283\u201399.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"4908_CR141","first-page":"1606","volume":"25","author":"Y-G Zhu","year":"2004","unstructured":"Zhu Y-G, Chen X-C, Chen Z-Z, Zeng Y-Q, Shi G-B, Su Y-H, et al. Curcumin protects mitochondria from oxidative damage and attenuates apoptosis in cortical neurons. Acta Pharmacol Sin. 2004;25:1606\u201312.","journal-title":"Acta Pharmacol Sin"},{"key":"4908_CR142","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fphar.2018.00183","volume":"9","author":"V Sorrenti","year":"2018","unstructured":"Sorrenti V, Contarini G, Sut S, Dall\u2019Acqua S, Confortin F, Pagetta A, et al. Curcumin prevents acute neuroinflammation and long-term memory impairment induced by systemic lipopolysaccharide in mice. Front Pharmacol. 2018;9:183.","journal-title":"Front Pharmacol"},{"issue":"9","key":"4908_CR143","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.euroneuro.2009.02.002","volume":"19","author":"T Ishrat","year":"2009","unstructured":"Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer\u2019s type (SDAT). Eur Neuropsychopharmacol. 2009;19(9):636\u201347.","journal-title":"Eur Neuropsychopharmacol"},{"key":"4908_CR144","first-page":"72","volume":"26","author":"NC Institute","year":"1996","unstructured":"Institute NC. Clinical development plan: curcumin. J Cell Biochem. 1996;26:72\u201385.","journal-title":"J Cell Biochem"},{"key":"4908_CR145","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.12659\/MSM.909042","volume":"24","author":"Z Shi","year":"2018","unstructured":"Shi Z, Qiu W, Xiao G, Cheng J, Zhang N. Resveratrol attenuates cognitive deficits of traumatic brain injury by activating p38 signaling in the brain. Med Sci Monit. 2018;24:1097\u2013103.","journal-title":"Med Sci Monit"},{"key":"4908_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.795409","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, He J, Huang Y, Hu Z. Resveratrol has an overall neuroprotective role in ischemic stroke: a meta-analysis in rodents. Front Pharmacol. 2021;12: 795409.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4908_CR147","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/nyas.13431","volume":"1403","author":"C Sawda","year":"2017","unstructured":"Sawda C, Moussa C, Turner RS. Resveratrol for Alzheimer\u2019s disease. Ann NY Acad Sci. 2017;1403(1):142\u20139.","journal-title":"Ann NY Acad Sci"},{"issue":"5","key":"4908_CR148","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","volume":"262","author":"EM Yiu","year":"2015","unstructured":"Yiu EM, Tai G, Peverill RE, Lee KJ, Croft KD, Mori TA, et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J Neurol. 2015;262(5):1344\u201353.","journal-title":"J Neurol"},{"issue":"Suppl 1","key":"4908_CR149","first-page":"S7","volume":"53","author":"L Almeida","year":"2009","unstructured":"Almeida L, Vaz-da-Silva M, Falc\u00e3o A, Soares E, Costa R, Loureiro AI, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53(Suppl 1):S7-15.","journal-title":"Mol Nutr Food Res"},{"key":"4908_CR150","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fnagi.2020.00103","volume":"12","author":"BD Arbo","year":"2020","unstructured":"Arbo BD, Andr\u00e9-Miral C, Nasre-Nasser RG, Schimith LE, Santos MG, Costa-Silva D, et al. Resveratrol derivatives as potential treatments for Alzheimer\u2019s and Parkinson\u2019s disease. Front Aging Neurosci. 2020;12:103.","journal-title":"Front Aging Neurosci"},{"key":"4908_CR151","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejpb.2018.02.010","volume":"127","author":"V Trotta","year":"2018","unstructured":"Trotta V, Pavan B, Ferraro L, Beggiato S, Traini D, Des Reis LG, et al. Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles. Eur J Pharm Biopharm. 2018;127:250\u20139.","journal-title":"Eur J Pharm Biopharm"},{"key":"4908_CR152","first-page":"299","volume":"3","author":"D Marx","year":"2015","unstructured":"Marx D, Williams G, Birkhoff M. Intranasal drug administration\u2014an attractive delivery route for some drugs drug discovery and development-from molecules to medicine. IntechOpen. 2015;3:299.","journal-title":"IntechOpen"},{"issue":"7","key":"4908_CR153","first-page":"2476","volume":"61","author":"E Shamsher","year":"2020","unstructured":"Shamsher E, Sulaimankutty R, Dine K, Luong V, Davis B, Willett K, et al. Intranasal delivery of resveratrol nanoparticles reduces retinal ganglion cell loss in a model of multiple sclerosis. Investig Ophthalmol Vis Sci. 2020;61(7):2476.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"4908_CR154","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.4103\/1673-5374.187049","volume":"11","author":"H-j Bao","year":"2016","unstructured":"Bao H-j, Qiu H-y, Kuai J-x, Song C-j, Wang S-x, Wang C-q, et al. Apelin-13 as a novel target for intervention in secondary injury after traumatic brain injury. Neural Regen Res. 2016;11(7):1128.","journal-title":"Neural Regen Res"},{"issue":"5","key":"4908_CR155","doi-asserted-by":"publisher","first-page":"175909141560511","DOI":"10.1177\/1759091415605114","volume":"7","author":"D Chen","year":"2015","unstructured":"Chen D, Lee J, Gu X, Wei L, Yu SP. Intranasal delivery of apelin-13 is neuroprotective and promotes angiogenesis after ischemic stroke in mice. ASN Neuro. 2015;7(5):1759091415605114.","journal-title":"ASN Neuro"},{"key":"4908_CR156","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mito.2016.05.005","volume":"29","author":"MR de Oliveira","year":"2016","unstructured":"de Oliveira MR. Evidence for genistein as a mitochondriotropic molecule. Mitochondrion. 2016;29:35\u201344.","journal-title":"Mitochondrion"},{"issue":"4","key":"4908_CR157","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/21691401.2017.1337024","volume":"46","author":"N Ahmad","year":"2018","unstructured":"Ahmad N, Ahmad R, Naqvi AA, Alam MA, Ashafaq M, Abdur Rub R, et al. Intranasal delivery of quercetin-loaded mucoadhesive nanoemulsion for treatment of cerebral ischaemia. Artif Cells Nanomed Biotechnol. 2018;46(4):717\u201329.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"4908_CR158","doi-asserted-by":"publisher","first-page":"7769355","DOI":"10.1155\/2022\/7769355","volume":"2022","author":"ZH Lin","year":"2022","unstructured":"Lin ZH, Liu Y, Xue NJ, Zheng R, Yan YQ, Wang ZX, et al. Quercetin protects against MPP(+)\/MPTP-induced dopaminergic neuron death in Parkinson\u2019s disease by inhibiting ferroptosis. Oxid Med Cell Longev. 2022;2022:7769355.","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"4908_CR159","doi-asserted-by":"publisher","first-page":"317","DOI":"10.32598\/bcn.9.5.317","volume":"9","author":"F Ghaffari","year":"2018","unstructured":"Ghaffari F, Hajizadeh Moghaddam A, Zare M. Neuroprotective effect of quercetin nanocrystal in a 6-hydroxydopamine model of parkinson disease: biochemical and behavioral evidence. Basic Clin Neurosci. 2018;9(5):317\u201324.","journal-title":"Basic Clin Neurosci"},{"issue":"1","key":"4908_CR160","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42826-021-00086-0","volume":"37","author":"DJ Park","year":"2021","unstructured":"Park DJ, Kang JB, Shah FA, Koh PO. Quercetin attenuates the reduction of parvalbumin in middle cerebral artery occlusion animal model. Lab Anim Res. 2021;37(1):9.","journal-title":"Lab Anim Res"},{"key":"4908_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121016","volume":"607","author":"P Papakyriakopoulou","year":"2021","unstructured":"Papakyriakopoulou P, Manta K, Kostantini C, Kikionis S, Banella S, Ioannou E, et al. Nasal powders of quercetin-\u03b2-cyclodextrin derivatives complexes with mannitol\/lecithin microparticles for nose-to-brain delivery: in vitro and ex vivo evaluation. Int J Pharm. 2021;607: 121016.","journal-title":"Int J Pharm"},{"key":"4908_CR162","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-16715-8","volume-title":"Therapeutic intranasal delivery for stroke and neurological disorders","author":"J Chen","year":"2019","unstructured":"Chen J, Wang J, Wei L, Zhang JH. Therapeutic intranasal delivery for stroke and neurological disorders. Cham: Springer; 2019."},{"issue":"5","key":"4908_CR163","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2174\/1871527317666180612125843","volume":"17","author":"S Wang","year":"2018","unstructured":"Wang S, Ma F, Huang L, Zhang Y, Peng Y, Xing C, et al. Dl-3-n-butylphthalide (NBP): a promising therapeutic agent for ischemic stroke. CNS Neurol Disord Drug Targets. 2018;17(5):338\u201347.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"4908_CR164","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/svn-2020-000364","volume":"6","author":"M Qu","year":"2021","unstructured":"Qu M, Zhao J, Zhao Y, Sun J, Liu L, Wei L, et al. Vascular protection and regenerative effects of intranasal DL-3-N-butylphthalide treatment after ischaemic stroke in mice. Stroke Vasc Neurol. 2021;6(1):74\u20139.","journal-title":"Stroke Vasc Neurol"},{"issue":"12","key":"4908_CR165","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1023\/A:1021614422668","volume":"27","author":"J Deutsch","year":"2002","unstructured":"Deutsch J, Rapoport SI, Rosenberger TA. Coenzyme A and short-chain acyl-CoA species in control and ischemic rat brain. Neurochem Res. 2002;27(12):1577\u201382.","journal-title":"Neurochem Res"},{"issue":"1","key":"4908_CR166","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1124\/jpet.105.087536","volume":"315","author":"R Mathew","year":"2005","unstructured":"Mathew R, Arun P, Madhavarao CN, Moffett JR, Namboodiri MA. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther. 2005;315(1):297\u2013303.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"4908_CR167","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161816","volume":"11","author":"TW Tefera","year":"2016","unstructured":"Tefera TW, Wong Y, Barkl-Luke ME, Ngo ST, Thomas NK, McDonald TS, et al. Triheptanoin protects motor neurons and delays the onset of motor symptoms in a mouse model of amyotrophic lateral sclerosis. PLoS ONE. 2016;11(8): e0161816.","journal-title":"PLoS ONE"},{"issue":"11","key":"4908_CR168","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1002\/jnr.24111","volume":"95","author":"F Mochel","year":"2017","unstructured":"Mochel F. Triheptanoin for the treatment of brain energy deficit: a 14-year experience. J Neurosci Res. 2017;95(11):2236\u201343.","journal-title":"J Neurosci Res"},{"issue":"4","key":"4908_CR169","doi-asserted-by":"publisher","first-page":"E860","DOI":"10.1152\/ajpendo.00366.2005","volume":"291","author":"RP Kinman","year":"2006","unstructured":"Kinman RP, Kasumov T, Jobbins KA, Thomas KR, Adams JE, Brunengraber LN, et al. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. Am J Physiol Endocrinol Metab. 2006;291(4):E860\u20136.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4908_CR170","unstructured":"Schiffmann R, Mochel F. Triheptanoin diet for adult polyglucosan body disease (apbd) treatment. Google Patents; 2011."},{"key":"4908_CR171","unstructured":"Matern D, Gavrilov DK. Fatty Acid Oxidation Disorders and Epilepsy. Inherited Metabolic Epilepsies. 2012."},{"issue":"49","key":"4908_CR172","doi-asserted-by":"publisher","first-page":"50754","DOI":"10.1074\/jbc.M408388200","volume":"279","author":"JR Revollo","year":"2004","unstructured":"Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754\u201363.","journal-title":"J Biol Chem"},{"issue":"1\u20133","key":"4908_CR173","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejphar.2006.05.039","volume":"543","author":"YS Diniz","year":"2006","unstructured":"Diniz YS, Rocha KK, Souza GA, Galhardi CM, Ebaid GM, Rodrigues HG, et al. Effects of N-acetylcysteine on sucrose-rich diet-induced hyperglycaemia, dyslipidemia and oxidative stress in rats. Eur J Pharmacol. 2006;543(1\u20133):151\u20137.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"4908_CR174","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.3390\/ijms20102451","volume":"20","author":"M Naoi","year":"2019","unstructured":"Naoi M, Wu Y, Shamoto-Nagai M, Maruyama W. Mitochondria in neuroprotection by phytochemicals: bioactive polyphenols modulate mitochondrial apoptosis system, function and structure. Int J Mol Sci. 2019;20(10):2451.","journal-title":"Int J Mol Sci"},{"key":"4908_CR175","doi-asserted-by":"publisher","first-page":"1184535","DOI":"10.3389\/fnut.2023.1184535","volume":"10","author":"A Nicolescu","year":"2023","unstructured":"Nicolescu A, Babot\u0103 M, Barros L, Rocchetti G, Lucini L, Tanase C, et al. Bioaccessibility and bioactive potential of different phytochemical classes from nutraceuticals and functional foods. Front Nutr. 2023;10:1184535.","journal-title":"Front Nutr"},{"issue":"10","key":"4908_CR176","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/brainsci9100275","volume":"9","author":"S Md","year":"2019","unstructured":"Md S, Alhakamy NA, Aldawsari HM, Asfour HZ. Neuroprotective and antioxidant effect of naringenin-loaded nanoparticles for nose-to-brain delivery. Brain Sci. 2019;9(10):275.","journal-title":"Brain Sci"},{"issue":"1\u20132","key":"4908_CR177","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijpharm.2018.03.055","volume":"543","author":"M Colombo","year":"2018","unstructured":"Colombo M, Figueir\u00f3 F, de Fraga DA, Teixeira HF, Battastini AMO, Koester LS. Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro. Int J Pharm. 2018;543(1\u20132):214\u201323.","journal-title":"Int J Pharm"},{"key":"4908_CR178","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijbiomac.2016.03.019","volume":"88","author":"N Ahmad","year":"2016","unstructured":"Ahmad N, Ahmad R, Alam MA, Samim M, Iqbal Z, Ahmad FJ. Quantification and evaluation of thymoquinone loaded mucoadhesive nanoemulsion for treatment of cerebral ischemia. Int J Biol Macromol. 2016;88:320\u201332.","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"4908_CR179","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.3390\/md13085156","volume":"13","author":"RC Cheung","year":"2015","unstructured":"Cheung RC, Ng TB, Wong JH, Chan WY. Chitosan: an update on potential biomedical and pharmaceutical applications. Mar Drugs. 2015;13(8):5156\u201386.","journal-title":"Mar Drugs"},{"key":"4908_CR180","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121246","author":"MC Bonferoni","year":"2020","unstructured":"Bonferoni MC, Rassu G, Gavini E, Sorrenti M, Catenacci L, Giunchedi P. Nose-to-brain delivery of antioxidants as a potential tool for the therapy of neurological diseases. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12121246.","journal-title":"Pharmaceutics"},{"key":"4908_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.615461","volume":"8","author":"J Prasuhn","year":"2020","unstructured":"Prasuhn J, Davis RL, Kumar KR. Targeting mitochondrial impairment in Parkinson\u2019s disease: challenges and opportunities. Front Cell Dev Biol. 2020;8: 615461.","journal-title":"Front Cell Dev Biol"},{"key":"4908_CR182","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"F Erd\u0151","year":"2018","unstructured":"Erd\u0151 F, Bors LA, Farkas D, Bajza \u00c1, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155\u201370.","journal-title":"Brain Res Bull"},{"issue":"3","key":"4908_CR183","first-page":"401","volume":"19","author":"I Tamai","year":"1996","unstructured":"Tamai I, Tsuji AJA. Drug delivery through the blood-brain barrier. Front Cell Dev Biol. 1996;19(3):401\u201324.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"4908_CR184","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/10903120802290778","volume":"13","author":"IH Black","year":"2009","unstructured":"Black IH, McManus J. Pain management in current combat operations. Prehosp Emerg Care. 2009;13(2):223\u20137.","journal-title":"Prehosp Emerg Care"},{"issue":"4","key":"4908_CR185","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.acpain.2007.09.001","volume":"9","author":"K Christensen","year":"2007","unstructured":"Christensen K, Rogers E, Green GA, Hamilton DA, Mermelstein F, Liao E, et al. Safety and efficacy of intranasal ketamine for acute postoperative pain. Acute Pain. 2007;9(4):183\u201392.","journal-title":"Acute Pain"},{"issue":"16","key":"4908_CR186","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/cbic.200800162","volume":"9","author":"A Mattarei","year":"2008","unstructured":"Mattarei A, Biasutto L, Marotta E, De Marchi U, Sassi N, Garbisa S, et al. A mitochondriotropic derivative of quercetin: a strategy to increase the effectiveness of polyphenols. ChemBioChem. 2008;9(16):2633\u201342.","journal-title":"ChemBioChem"},{"issue":"20","key":"4908_CR187","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.7150\/thno.29039","volume":"8","author":"A Sharma","year":"2018","unstructured":"Sharma A, Liaw K, Sharma R, Zhang Z, Kannan S, Kannan RM. Targeting mitochondrial dysfunction and oxidative stress in activated microglia using dendrimer-based therapeutics. Theranostics. 2018;8(20):5529\u201347.","journal-title":"Theranostics"},{"issue":"2","key":"4908_CR188","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40199-019-00283-2","volume":"27","author":"W Hasan","year":"2019","unstructured":"Hasan W, Kori RK, Thakre K, Yadav RS, Jat D. Synthesis, characterization and efficacy of mitochondrial targeted delivery of TPP-curcumin in rotenone-induced toxicity. Daru. 2019;27(2):557\u201370.","journal-title":"Daru"},{"issue":"9","key":"4908_CR189","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/molecules14093754","volume":"14","author":"Y Ozsoy","year":"2009","unstructured":"Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules. 2009;14(9):3754\u201379.","journal-title":"Molecules"},{"issue":"3","key":"4908_CR190","doi-asserted-by":"publisher","first-page":"288","DOI":"10.18433\/J3NC79","volume":"12","author":"A Pires","year":"2009","unstructured":"Pires A, Fortuna A, Alves G, Falc\u00e3o A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12(3):288\u2013311.","journal-title":"J Pharm Pharm Sci"},{"issue":"3","key":"4908_CR191","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1542\/peds.2010-0616","volume":"126","author":"TR Wolfe","year":"2010","unstructured":"Wolfe TR, Braude DA. Intranasal medication delivery for children: a brief review and update. Pediatrics. 2010;126(3):532\u20137.","journal-title":"Pediatrics"},{"issue":"2","key":"4908_CR192","first-page":"67","volume":"4","author":"YW Chien","year":"1987","unstructured":"Chien YW, Chang SF. Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carrier Syst. 1987;4(2):67\u2013194.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"5","key":"4908_CR193","first-page":"600","volume":"50","author":"PV Turner","year":"2011","unstructured":"Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50(5):600\u201313.","journal-title":"J Am Assoc Lab Anim Sci"},{"issue":"1","key":"4908_CR194","first-page":"1","volume":"10","author":"MC Veronesi","year":"2020","unstructured":"Veronesi MC, Alhamami M, Miedema SB, Yun Y, Ruiz-Cardozo M, Vannier MW. Imaging of intranasal drug delivery to the brain. Am J Nucl Med Mol Imaging. 2020;10(1):1\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"4908_CR195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40824-019-0166-x","volume":"23","author":"D Chenthamara","year":"2019","unstructured":"Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin F-H, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomaterials Research. 2019;23(1):1\u201329.","journal-title":"Biomaterials Research"},{"key":"4908_CR196","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.979682","volume":"13","author":"A Rajput","year":"2022","unstructured":"Rajput A, Pingale P, Dhapte-Pawar V. Nasal delivery of neurotherapeutics via nanocarriers: facets, aspects, and prospects. Front Pharmacol. 2022;13: 979682.","journal-title":"Front Pharmacol"},{"issue":"11","key":"4908_CR197","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1021\/acs.bioconjchem.7b00515","volume":"28","author":"D Wang","year":"2017","unstructured":"Wang D, Ren Y, Shao Y, Yu D, Meng L. Facile preparation of doxorubicin-loaded and folic acid-conjugated carbon nanotubes@Poly(N-vinyl pyrrole) for targeted synergistic chemo-photothermal cancer treatment. Bioconjug Chem. 2017;28(11):2815\u201322.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"4908_CR198","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1039\/D0NA00869A","volume":"3","author":"M Soligo","year":"2021","unstructured":"Soligo M, Felsani FM, Da Ros T, Bosi S, Pellizzoni E, Bruni S, et al. Distribution in the brain and possible neuroprotective effects of intranasally delivered multi-walled carbon nanotubes. Nanoscale Adv. 2021;3(2):418\u201331.","journal-title":"Nanoscale Adv"},{"issue":"5","key":"4908_CR199","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jpha.2019.04.003","volume":"9","author":"D Mohanta","year":"2019","unstructured":"Mohanta D, Patnaik S, Sood S, Das N. Carbon nanotubes: Evaluation of toxicity at biointerfaces. J Pharm Anal. 2019;9(5):293\u2013300.","journal-title":"J Pharm Anal"},{"issue":"11","key":"4908_CR200","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080964","volume":"8","author":"G Bardi","year":"2013","unstructured":"Bardi G, Nunes A, Gherardini L, Bates K, Al-Jamal KT, Gaillard C, et al. Functionalized carbon nanotubes in the brain: cellular internalization and neuroinflammatory responses. PLoS ONE. 2013;8(11): e80964.","journal-title":"PLoS ONE"},{"key":"4908_CR201","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.mito.2017.03.004","volume":"34","author":"JD McCully","year":"2017","unstructured":"McCully JD, Cowan DB, Emani SM, Pedro J. Mitochondrial transplantation: from animal models to clinical use in humans. Mitochondrion. 2017;34:127\u201334.","journal-title":"Mitochondrion"},{"issue":"1","key":"4908_CR202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-82884-z","volume":"11","author":"GJ Shami","year":"2021","unstructured":"Shami GJ, Cheng D, Verhaegh P, Koek G, Wisse E, Braet F. Three-dimensional ultrastructure of giant mitochondria in human non-alcoholic fatty liver disease. Sci Rep. 2021;11(1):1\u201314.","journal-title":"Sci Rep"},{"issue":"7","key":"4908_CR203","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.7150\/thno.53474","volume":"11","author":"JF Alexander","year":"2021","unstructured":"Alexander JF, Seua AV, Arroyo LD, Ray PR, Wangzhou A, Hei\u03b2-L\u00fcckemann L, et al. Nasal administration of mitochondria reverses chemotherapy-induced cognitive deficits. Theranostics. 2021;11(7):3109\u201330.","journal-title":"Theranostics"},{"key":"4908_CR204","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.biocel.2014.05.009","volume":"53","author":"CS Liu","year":"2014","unstructured":"Liu CS, Chang JC, Kuo SJ, Liu KH, Lin TT, Cheng WL, et al. Delivering healthy mitochondria for the therapy of mitochondrial diseases and beyond. Int J Biochem Cell Biol. 2014;53:141\u20136.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"4908_CR205","doi-asserted-by":"publisher","first-page":"H94","DOI":"10.1152\/ajpheart.00567.2008","volume":"296","author":"JD McCully","year":"2009","unstructured":"McCully JD, Cowan DB, Pacak CA, Toumpoulis IK, Dayalan H, Levitsky S. Injection of isolated mitochondria during early reperfusion for cardioprotection. Am J Physiol Heart Circ Physiol. 2009;296(1):H94-h105.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"4908_CR206","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/mp.2015.166","volume":"21","author":"DS Quintana","year":"2016","unstructured":"Quintana DS, Guastella AJ, Westlye LT, Andreassen OA. The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders. Mol Psychiatry. 2016;21(1):29\u201338.","journal-title":"Mol Psychiatry"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04908-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-04908-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04908-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T16:09:55Z","timestamp":1708358995000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-04908-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":206,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4908"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-04908-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The opinions or assertions contained herein are the private views of the authors and are not to be construed as official, or as reflecting true views of the Department of the Army, or the Department of Defense, or the Defense Health Agency. No experimental studies were conducted to generate any preclinical or clinical data for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and\/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}